Posaconazole for the treatment of mucormycosis

David Enoch*, S. H. Aliyu, O. Sule, S. J. Lewis, J. A. Karas

*Corresponding author for this work

    Research output: Contribution to journalShort surveypeer-review

    21 Citations (Scopus)

    Abstract

    Posaconazole (PCZ) is an orally administered, extended-spectrum triazole antifungal agent with activity against the Mucorales. This article describes the clinical and laboratory data supporting its use against this rare group of pathogens. To date, PCZ has been mostly used for salvage therapy and at present there is no strong published clinical evidence to support its role as a single agent in the treatment of mucormycosis. Further studies are required to explore its role as a single agent and in combination therapy for the management of these infections.

    Original languageEnglish
    Pages (from-to)465-473
    Number of pages9
    JournalInternational Journal of Antimicrobial Agents
    Volume38
    Issue number6
    DOIs
    Publication statusPublished - Dec 2011

    Keywords

    • Antifungal agents
    • Mucormycosis
    • Posaconazole
    • Triazoles

    Fingerprint

    Dive into the research topics of 'Posaconazole for the treatment of mucormycosis'. Together they form a unique fingerprint.

    Cite this